Does the handling time of unrefrigerated human fecal specimens impact the detection of Clostridium difficile toxins in a hospital setting?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The stability of Clostridium difficile toxins is an important factor in determining the accuracy of the enzyme immunoassay (EIA). The Centers for Disease Control has stated that C. difficile toxins may become undetectable in unrefrigerated stool specimens within 2 h after collection.
The purpose of our study was to determine how the unrefrigerated handling time of human fecal specimens affects the results of C. difficile infection (CDI) testing.
A retrospective review of CDI testing with Premier™ Toxins A and B kit was conducted in northern New Jersey, USA. Stool collection times and receiving times were recorded for each specimen. The unrefrigerated handling time was calculated for each.
A total of 1126 fecal specimens were submitted. We excluded 72 fecal specimens due to incomplete documentation. We included 1054 fecal specimens collected from 636 hospitalized patients. A total of 132 out of 1054 specimens (12.5%) tested positive for C. difficile toxins. Nine hundred and fifty-four specimens were unrefrigerated for 13 h or less, of which 127 (13.3%) tested positive. Five (5%) of the 100 specimens that were unrefrigerated for more than 13 h tested positive (p = 0.02).
C. difficile toxins can still be detected up to 13 h after collection in unrefrigerated human fecal specimens. However, fecal specimens should be processed according to the current recommendations to ensure the reliability of EIA testing until the results of our study are confirmed with prospective studies.
- Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Inter Med. 2009;151:176–9.
- McFarland LV. Renewed interested in a difficult disease: Clostridium difficile infections—Epidemiology and current treatment strategies. Curr Opin Gastroenterol. 2009;25:24–35. CrossRef
- Klingler PJ, Metzger PP, Seelig MH, Pettit PD, Knudsen JM, Alvarez SA. Clostridium difficile infection: risk factors, medical and surgical management. Dig Dis Sci. 2000;18:147–60. CrossRef
- Arrow SA, Croese L, Bowman RA, Riley TV. Evaluation of three commercial enzyme immunoassay kits for detecting fecal Clostridium difficile toxins. J Clin Pathol. 1994;47:954–6. CrossRef
- Lozniewski A, Rabaud C, Dotto M, Weber M, Mory F. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of premier cytoclone A+B enzyme immunoassay for combined detection of fecal toxins and toxigenic C. difficile strains. J Clin Microbiol. 2001;39:1996–8. CrossRef
- Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol. 2003;41:531–4. CrossRef
- Hafiz S, Oakley CL. Clostridium difficile: isolation and characteristics. J Med Microbiol. 1976;9:129–36. CrossRef
- Weese JS, Staempfli HR, Prescott JF. Survival of Clostridium difficile and its toxins in equine feces: implications for diagnostic test selection and interpretation. J Vet Diagn Invest. 2000;12:332–6.
- Buggy BP, Wilson KH, Fekety R. Comparison of methods for recovery of clostridium difficile from an environmental surface. J Clin Microbiol. 1983;18:348–52.
- Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudo membranous colitis due to toxin producing clostridia. N Engl J Med. 1978;289:531–4. CrossRef
- Center for Disease Control and Prevention. Frequently asked questions, information for healthcare providers. Released August 2004; Updated 07/22/2005. Web page accessed 03/23/ 2010, available via http://www.cdc.gov/ncidod/dhqp/id_CdiffFAQ_HCP.html
- Onderdonk AB, Allen SD. Clostridium. In: Murray PR, editor. Manual of Clinical Microbiology. Washington: ASM Press; 1995. p. 574–86.
- Kader HA, Piccoli DA, Jawad AF, et al. Single toxin detection is inadequate to diagnose Clostridium difficile diarrhea in pediatric patients. Gastroenterology. 1998;115:1329–34. CrossRef
- Bowman RA, Riley TV. Isolation of Clostridium difficile from stored specimens and comparative susceptibility of various tissue culture cell lines to cytotoxin. FEMS Microbiol Lett. 1986;34:31–5. CrossRef
- Jones RL. Diagnostic procedures for isolation and characterization of Clostridium difficile associated with enterocolitis in foals. J Vet Diagn Invest. 1989;1:84–6.
- Staneck JL, Weckbach LS, Allen SD, et al. Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C. difficile, cytotoxin assay, culture, and latex agglutination. J Clin Microbiol. 1996;34:2718–21.
- Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol. 2008;46:1996–2001. CrossRef
- Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol. 2009;47:373–8. CrossRef
- Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60. CrossRef
- Eggertson LC. difficile: by the numbers. CMAJ. 2004;171:1331–2.
- Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hyper virulent strain in Quebec. CMAJ. 2005;173:1037–42.
- Alfa M, Du T, Beda G. Survey of incidence of Clostridium difficileinfection in Canadian hospitals and diagnostic approaches. J Clin Microbiol. 1998;36:2076–80.
- Labbe' AC, Poirier L, MacCannell D, et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a Regional Epidemic Associated with the BI/NAP1/027 Strain. Antimicrob Agents Chemother. 2008;52:3180–87. CrossRef
- McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–41. CrossRef
- Warny M, Pépin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84. CrossRef
- Does the handling time of unrefrigerated human fecal specimens impact the detection of Clostridium difficile toxins in a hospital setting?
Indian Journal of Gastroenterology
Volume 29, Issue 4 , pp 157-161
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Handling time
- Human fecal specimen
- Toxin A and B stability
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology, Saint Michael’s Medical Center, 111 Central Ave, Newark, NJ, 07102, USA
- 4. Seton Hall University School of Health and Medical Sciences, South Orange, NJ, USA
- 2. Department of Medical Education, Saint Michael’s Medical Center, 111 Central Ave, Newark, NJ, 07102, USA
- 3. Department of Infectious Disease, Saint Michael’s Medical Center, Newark, NJ, USA